Previous ineligibility for or treatment failure of ciclosporin does not influence lebrikizumab efficacy in atopic dermatitis

Zenas Z N Yiu^{1

2}

Affiliations

¹ Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
² Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Editorial

Zenas Z N Yiu. Br J Dermatol. 2025.

. 2025 Oct 17;193(5):812-813.

doi: 10.1093/bjd/ljaf316.

Zenas Z N Yiu^{1

2}

¹ Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
² Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

No abstract available

Conflict of interest statement

Conflicts of interest: Z.Z.N.Y.’s research department participated as a recruiting centre in this trial.

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).
Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S. Warren RB, et al. Br J Dermatol. 2025 Oct 17;193(5):876-888. doi: 10.1093/bjd/ljaf285. Br J Dermatol. 2025. PMID: 40985295 Clinical Trial.